Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) just unveiled an update.
RemeGen Co., Ltd. announced that its drug, disitamab vedotin, has received marketing approval in China for treating HER2-positive advanced breast cancer with liver metastasis. This approval, based on a Phase III clinical study, marks a significant advancement in treatment options for this aggressive cancer type, potentially impacting the company’s market position and offering new hope for patients with limited treatment options.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a pharmaceutical company based in China, specializing in the development of innovative antibody-drug conjugates (ADCs) targeting cancer treatment. The company focuses on creating drugs that target specific proteins on tumor cells, with products that have gained recognition for their clinical value in treating various cancers, including gastric and uroepithelial carcinoma.
Average Trading Volume: 7,948,766
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.63B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.